

HW

USSN: 10/643,679 Atty. Docket No.: PP001612.0009

(2300-1612.10)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 10,2007

By:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

PALIARD et al.

U.S. Application No.

10/643,679

Date Filed:

August 18, 2003

Group Art Unit:

1648

Examiner:

Bao Oun Li

For:

ACTIVATION OF HCV-SPECIFIC T CELLS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97(c)(2)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

The citations listed on the enclosed Information Disclosure Form (Forms PTO/SB/08A and PTO/SB/08B) may be material to the examination of the above-identified patent application. Therefore, Applicant submits these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56 and §1.97(c)(2). The Examiner is respectfully requested to make these citations of official record in the present application and return an initialed copy of the attached Forms PTO/SB/08A and PTO/SB/08B to the undersigned.

USSN: 10/643,679 Atty. Docket No.: PP001612.0009

(2300-1612.10)

The present Information Disclosure Statement is being filed after the period specified in 37 C.F.R. §1.97(b) and before the mailing date of a final action, a notice of allowance, or an action otherwise closes prosecution in the current application. Therefore, we hereby submit the fee under 37 C.F.R. §1.17(p).

No copies of the publications listed on the attached Form PTO/SB/08A or PTO/SB/08B are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. 10/357,619 to which the above-identified application claims priority under 35 U.S.C. \$120.

This Information Disclosure Statement under 37 C.F.R. §1.56 and §1.97(c)(2) is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Date: April 10, 2007

Respectfully submitted,

By:

Mei Hong

Agent for Applic

Agent for Applicants Reg. No. 55,276

NOVARTIS VACCINES AND DIAGNOSTICS, INC. Intellectual Property - R440

P.O. Box 8097

Emeryville, CA 94662-8097 Telephone: (510) 923-5413 Facsimile: (510) 655-3542

USSN: 10/643,679 Atty. Docket No.: PP001612.0009

(2300-1612.10)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 10, 2007

APR 16 2007

y: Muchelle If

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

PALIARD et al.

U.S. Application No.

10/643,679

Date Filed:

August 18, 2003

Group Art Unit:

1642

Examiner:

Bao Qun Li

For:

ACTIVATION OF HCV-SPECIFIC T CELLS

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is an Information Disclosure Statement and accompanying Forms PTO/SB/08A and PTO/SB/08B for the above-identified patent application.

- [] In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.
- [x] In accordance with 37 C.F.R. §1.97(c), also enclosed is:
  - [x] the fee of \$180.00 as set forth in 37 C.F.R. 1.17(p); or
  - [] a statement as specified in 37 C.F.R. §1.97(e).

USSN: 10/643,679 Atty. Docket No.: PP001612.0009 (2300-1612.10)

[] In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. §1.97 (e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.

- [] Check No. \_\_\_\_ in the amount of \$\_\_\_\_ for total fee is attached.
- [X] A return receipt postcard is also enclosed.
- [x] Please charge \$ 180.00 to Deposit Account No. 03-1664 for the total fee. This paper is being submitted in duplicate.

The Commissioner for Patents is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication and which may be required under 37 CFR 1.16 and 1.17 to Deposit Account No. 03-1664.

Respectfully submitted,

By:

Mei Hong, Ph. D. Agent for Applicants Reg. No. 55,276

Date: April 10, 2007

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Intellectual Property - R440

P.O. Box 8097

Emeryville, CA 94662-8097 Telephone: (510) 923-5413 Facsimile: (510) 655-3542

PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/643,679		
Filing Date	August 18, 2003		
First Named Inventor	Paliard		
Art Unit	1648		
Examiner Name	Bao Qun Li		
Attorney Docket Number	PP001612 0009		

	Cite	Number-Kind Code <sup>2</sup> (# known) MM-DD-YYYY	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
	No.1		MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevar Figures Appear
		<sup>US-</sup> 4,919,929	04-24-1990	Beck, Lee R.	
		<sup>US-</sup> 5,610,009	03-11-1997	Watanabe et al.	
		<sup>US-</sup> 6,312,889	11-06-2001	Houghton et al.	
		<sup>US-</sup> 6,986,892	01-17-2006	Coit et al.	
		US-			•
		US-			
		US-			
		US-			
		US-		·	
		US-			
		US-			
		ÜS-			
		US-			
		US-			

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
		WO 93/10239	05-27-1993	Simmonds et al.		
		WO 98/50556	11-12-1998	Houghton et al.		
		WO 94/27718	12-08-1994	O'Hagan et al.		
		WO 96/38474	12-05-1996	Liao et al.		
		WO 03/031588	04-17-2003	Merck & Co., Inc.		
		WO 99/38880A1	08-05-1999	Wands et al.		

Examiner	 Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\)Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
Sabelina (1877) (1877)	Application Number	10/643,679	
INFORMATION DISCLOSURE	Filing Date	August 18, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Paliard et al.	
(Use as many sheets as necessary)	Art Unit	1648	
(Ose as many sheets as necessary)	Examiner Name	Bao Qun Li	
Sheet of	Attorney Docket Number	PP001612.0009	

	T 0'4	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Zhang et al., Clinical and Diagnostic Laboratory Immunology, Volume 1 No. 3, pages 290-94 (May 1994).	
		Fournillier et al., Journal of Virology, Volume 73 No. 9, pages 7497-9504 (September 1999).	
		Seong et al., Vaccine, Volume 19 Nos. 20-22, pages 2955-64 (April 2001).	
		Saito et al., Gatroenterology, Volume 112 No 4, pages 1321-1330 (April 1997).	
		·	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.